Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Asuragen gets notices of allowance for mir-21, mir-30a claims

Asuragen, a provider in the development of molecular diagnostics, had received notices of allowance from the US Patent and Trademark Office (USPTO) for claims related to the use of mir-21 and mir-30a as diagnostics in lung cancer.

miR-21 has been implicated as a possible therapeutic target and in several clinically relevant diagnostic applications, including potential improvements in early detection and more informed prognosis of lung cancer.

Human miR-21 acts as a marker for use as a diagnostic for lung cancer as it will be highly expressed in lung cancer compared to normal patients.

Asuragen plans to launch its first miRNA kit, a miR-21 (RUO) kit for the detection of mir-21 expression levels, in the second quarter of this year.

Asuragen CEO and CSO Matt Winkler said they were the first company to launch a clinically validated miRNA-based diagnostic test and now are poised to launch their first miRNA-based detection kit.

"We are beginning to see a steady stream of allowances from our early miRNA patent filings which highlight our early pioneering work in the development of microRNA technologies for health care applications," Winkler said.